Extracorporeal Membrane Oxygenation Therapy for Critically Ill Coronavirus Disease 2019 Patients in Wuhan, China: A Retrospective Multicenter Cohort Study

Abstract

Currently, little in-depth evidence is known about the application of extracorporeal membrane oxygenation (ECMO) therapy in coronavirus disease 2019 (COVID-19) patients. This retrospective multicenter cohort study included patients with COVID-19 at 7 designated hospitals in Wuhan, China. The patients were followed up until June 30, 2020. Univariate and multivariate logistic regression analyses were performed to identify the risk factors associated with unsuccessful ECMO weaning. Propensity score matching was used to match patients who received veno-venous ECMO with those who received invasive mechanical ventilation (IMV)-only therapy. Of 88 patients receiving ECMO therapy, 27 and 61 patients were and were not successfully weaned from ECMO, respectively. Additionally, 15, 15, and 65 patients were further weaned from IMV, discharged from hospital, or died during hospitalization, respectively. In the multivariate logistic regression analysis, a lymphocyte count ≤0.5×10⁹/L and D-dimer concentration >4× the upper limit of normal level at ICU admission, a peak PaCO₂ >60 mmHg at 24 h before ECMO initiation, and no tracheotomy performed during the ICU stay were independently associated with lower odds of ECMO weaning. In the propensity score-matched analysis, a mixed-effect Cox model detected a lower hazard ratio for 120-day all-cause mortality after ICU admission during hospitalization in the ECMO group. The presence of lymphocytopenia, higher D-dimer concentrations at ICU admission and hypercapnia before ECMO initiation could help to identify patients with a poor prognosis. Tracheotomy could facilitate weaning from ECMO. ECMO relative to IMV-only therapy was associated with improved outcomes in critically ill COVID-19 patients.

Keywords

coronavirus disease 2019 / extracorporeal membrane oxygenation / mechanical ventilation / acute respiratory distress syndrome / viral pneumonia

References

[1] RichardsonS, HirschJS, NarasimhanM, et al.. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA, 2020, 323(20): 2052-2059

[2] DaviesA, JonesD, BaileyM, et al.. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA, 2009, 302(17): 1888-1895

[3] NoahMA, PeekGJ, FinneySJ, et al.. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA, 2011, 306(15): 1659-1668

[4] LiX, GuoZ, LiB, et al.. Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China. ASAIO J, 2020, 66(5): 475-481

[5] HenryBM, LippiG. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports. J CRIT CARE, 2020, 58: 27-28

[6] LangoR, SzkulmowskiZ, MaciejewskiD, et al.. Revised protocol of extracorporeal membrane oxygenation (ECMO) therapy in severe ARDS. Recommendations of the veno-venous ECMO expert panel appointed in February 2016 by the national consultant on anesthesiology and intensive care. Anaesthesiol Intensive Ther, 2017, 49(2): 88-99

[7] KellumJA, LameireN, AspelinP, et al.. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2012, 2(1): 1-138

[8] LeiF, LiuYM, ZhouF, et al.. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology, 2020, 72(2): 389-398

[9] GandoS, WadaH, ThachilJ. Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS). J Thromb Haemost, 2013, 11(5): 826-835

[10] WaljeeAK, MukherjeeA, SingalAG, et al.. Comparison of imputation methods for missing laboratory data in medicine. BMJ OPEN, 2013, 3(8): e2847

[11] CombesA, HajageD, CapellierG, et al.. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. New Engl J Med, 2018, 378(21): 1965-1975

[12] AlshahraniMS, SindiA, AlshamsiF, et al.. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care, 2018, 8(1): 3

[13] PanA, LiuL, WangC, et al.. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA, 2020, 323(19): 1-9

[14] BroganTV, ThiagarajanRR, RycusPT, et al.. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database. Intens Care Med, 2009, 35(12): 2105-2114

[15] DelmasC, ZapetskaiaT, ConilJM, et al.. 3-month prognostic impact of severe acute renal failure under veno-venous ECMO support: Importance of time of onset. J Crit Care, 2018, 44: 63-71

[16] SchmidtM, BaileyM, SheldrakeJ, et al.. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The respiratory extracorporeal membrane oxygenation survival prediction (RESP) score. Am J Resp Crit Care, 2014, 189(11): 1374-1382

[17] NucktonTJ, AlonsoJA, KalletRH, et al.. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med, 2002, 346(17): 1281-1286

[18] MenterT, HaslbauerJD, NienholdR, et al.. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology, 2020, 77(2): 198-209

[19] ZhangL, YanX, FanQ, et al.. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost, 2020, 18(6): 1324-1329

[20] ZhouF, YuT, DuR, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062

[21] TangN, BaiH, ChenX, et al.. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost, 2020, 18(5): 1094-1099

[22] WangD, HuB, HuC, et al.. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069

[23] ChenG, WuD, GuoW, et al.. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest, 2020, 130(5): 2620-2629

[24] HenryBM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med, 2020, 8(4): e24

[25] PeekGJ, MugfordM, TiruvoipatiR, et al.. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet, 2009, 374(9698): 1351-1363